Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL studyElena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Leukemia|May 20, 2021
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patientsTiziano Barbui, Valerio De Stefano, Alessandra Carobbio, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Leukemia Research|June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL studyElena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Leukemia|May 20, 2021
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patientsTiziano Barbui, Valerio De Stefano, Alessandra Carobbio, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Leukemia Research|June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Pageof 13